2001
DOI: 10.1093/ajhp/58.12.1133
|View full text |Cite
|
Sign up to set email alerts
|

Economic burden of influenza-like illness in long-term-care facilities

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2003
2003
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(5 citation statements)
references
References 0 publications
0
5
0
Order By: Relevance
“…Prescription and OTC drug costs were analysed in 12 and 13 studies respectively. The mean prescription drug cost per episode ranges from US$1 in UK [ 36 ], Norway [ 25 ], and Korea [ 32 ], to US$ 60 in the US [ 14 ], whereas in Europe, the maximum identified cost per episode was found in Germany (US$16) [ 38 ]. The expected OTC expenditure per episode ranges between US$2 in Italy [ 26 ] and US$13 in Australia and Germany [ 16 , 37 ], and their impact varied between 2.8% and 18.6% of total health care costs and between 13.2% and 88.9% of total drug costs.…”
Section: Resultsmentioning
confidence: 99%
“…Prescription and OTC drug costs were analysed in 12 and 13 studies respectively. The mean prescription drug cost per episode ranges from US$1 in UK [ 36 ], Norway [ 25 ], and Korea [ 32 ], to US$ 60 in the US [ 14 ], whereas in Europe, the maximum identified cost per episode was found in Germany (US$16) [ 38 ]. The expected OTC expenditure per episode ranges between US$2 in Italy [ 26 ] and US$13 in Australia and Germany [ 16 , 37 ], and their impact varied between 2.8% and 18.6% of total health care costs and between 13.2% and 88.9% of total drug costs.…”
Section: Resultsmentioning
confidence: 99%
“…Costs were mainly driven by inpatient costs, which were 84% of total costs. 9 In Asia, published evidence on the economic burden of influenza is limited. In Australia, the estimated total direct influenza cost in people of all ages, in the absence of vaccination, was estimated at AU$115 million annually to the Australian health care system (AU$33.32 per consultation and between AU$5413 and AU$5986 per case of hospitalization).…”
Section: Background and Objectivesmentioning
confidence: 99%
“…14 Influenza and pneumococcal vaccinations are cost-effective and efficacious in containing disease in these settings. 5 The Advisory Committee on Immunization Practices recommends influenza vaccination for those living in LTCFs 6 and pneumococcal vaccination for patients in "certain social circumstances," which would include these residents for various reasons. 7 Immunization of all residents facilitates the benefits of herd immunity or protection for other residents in the facility.…”
mentioning
confidence: 99%